We characterized the proteomic composition of RBCs from 53 breast cancer patients (stages I-III and IV), compared with 33 healthy donors. For that, we performed two different proteomic analyses (LC-MS/MS in DDA mode-shotgun- and a SWATH-MS) using the Triple TOF 6600 technology.